Harald Wajant Selected Research

Type I Tumor Necrosis Factor Receptors

5/2022	Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy.
1/2021	Quantitative single-molecule imaging of TNFR1 reveals zafirlukast as antagonist of TNFR1 clustering and TNFα-induced NF-ĸB signaling.
1/2020	Single-molecule imaging reveals the oligomeric state of functional TNFα-induced plasma membrane TNFR1 clusters in cells.
1/2019	Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice.
1/2019	The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death.
2/2014	Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor.
6/2013	Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.
1/2013	Tumor necrosis factor induces tumor promoting and anti-tumoral effects on pancreatic cancer via TNFR1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harald Wajant Research Topics

Disease

36	Neoplasms (Cancer) 05/2022 - 11/2002
9	Inflammation (Inflammations) 01/2020 - 01/2004
5	Necrosis 01/2021 - 01/2003
5	Multiple Myeloma 12/2019 - 09/2012
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 07/2015
4	Carcinoma (Carcinomatosis) 01/2021 - 04/2014
3	Multiple Sclerosis 01/2021 - 02/2014
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2014 - 04/2005
2	Autoimmune Diseases (Autoimmune Disease) 05/2022 - 01/2019
2	Medulloblastoma 01/2022 - 01/2020
2	Experimental Arthritis 01/2022 - 01/2019
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 01/2021
2	Leukemia 11/2019 - 03/2017
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2017 - 07/2015
2	Colitis 07/2015 - 06/2006
2	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2014 - 01/2011
2	Neoplasm Metastasis (Metastasis) 06/2013 - 03/2008
2	Sarcoma (Soft Tissue Sarcoma) 07/2009 - 01/2009
1	Bites and Stings (Sting) 01/2022
1	Rheumatoid Arthritis 01/2021
1	Breast Neoplasms (Breast Cancer) 11/2019
1	Fibrosarcoma 11/2019
1	Autoimmune Lymphoproliferative Syndrome 11/2019
1	Heart Failure 01/2019
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2019
1	Arthritis (Polyarthritis) 01/2019
1	Lymphopenia (Lymphocytopenia) 01/2018
1	Wilms Tumor (Wilm's Tumor) 03/2017
1	Infections 09/2014
1	B-Cell Leukemia (Leukemia, B Cell) 04/2014
1	Melanoma (Melanoma, Malignant) 06/2013
1	Pancreatic Ductal Carcinoma 01/2013
1	Myocardial Infarction 01/2013
1	Parkinson Disease (Parkinson's Disease) 01/2011
1	Adenocarcinoma 07/2010
1	Acantholysis 01/2009
1	Skin Diseases (Skin Disease) 01/2009
1	Pemphigus (Pemphigus Vulgaris) 01/2009

Drug/Important Bio-Agent (IBA)

19	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 11/2002
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2002
12	LigandsIBA 01/2020 - 11/2002
11	Death Domain ReceptorsIBA 07/2019 - 11/2002
10	Type II Tumor Necrosis Factor ReceptorsIBA 05/2022 - 01/2013
10	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2021 - 01/2003
8	Type I Tumor Necrosis Factor ReceptorsIBA 05/2022 - 01/2013
7	CytokinesIBA 01/2018 - 02/2005
3	AntibodiesIBA 01/2021 - 07/2010
3	AntigensIBA 01/2020 - 05/2008
3	TNF-Related Apoptosis-Inducing LigandIBA 01/2018 - 01/2003
3	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 07/2015 - 01/2013
3	Surface Antigens (Surface Antigen)IBA 01/2012 - 08/2003
3	Fas Ligand Protein (Fas Ligand)IBA 01/2006 - 02/2003
2	Tumor Necrosis Factor InhibitorsIBA 05/2022 - 01/2019
2	Etanercept (Enbrel)FDA Link 01/2021 - 03/2008
2	Immune Checkpoint InhibitorsIBA 01/2020 - 03/2014
2	pevonedistatIBA 01/2019 - 01/2013
2	Indicators and Reagents (Reagents)IBA 01/2012 - 08/2003
2	NF-kappa B (NF-kB)IBA 07/2010 - 01/2004
2	ProdrugsIBA 07/2009 - 12/2006
1	A-factor (Streptomyces)IBA 05/2022
1	zafirlukast (Accolate)FDA LinkGeneric 01/2021
1	Lymphotoxin-alpha (Lymphotoxin)IBA 01/2020
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 12/2019
1	jozimine A2IBA 11/2019
1	Caspase 8 (Caspase-8)IBA 11/2019
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 07/2019
1	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2019
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2019
1	Pattern Recognition ReceptorsIBA 01/2019
1	Collagen Type II (Type II Collagen)IBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2018
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2017
1	CaspasesIBA 01/2017
1	LCL161IBA 01/2017
1	SuperantigensIBA 09/2014
1	Immunoglobulin FragmentsIBA 04/2014
1	Epithelial Cell Adhesion MoleculeIBA 04/2014
1	CD40 Ligand (CD40L)IBA 04/2014
1	MicroRNAs (MicroRNA)IBA 01/2014
1	Cell Surface ReceptorsIBA 01/2013
1	3- (4- methylphenylsulfonyl)- 2- propenenitrileIBA 01/2013
1	integrin-linked kinaseIBA 09/2012
1	QLT 0267IBA 09/2012
1	Single-Chain AntibodiesIBA 01/2012
1	Radioisotopes (Radionuclides)IBA 01/2012
1	Oxidopamine (6 Hydroxydopamine)IBA 01/2011
1	mapatumumabIBA 07/2010
1	Interleukin-8 (Interleukin 8)IBA 07/2010
1	lexatumumabIBA 07/2010
1	Keratins (Keratin)IBA 01/2009
1	Recombinant ProteinsIBA 01/2009
1	AutoantibodiesIBA 01/2009
1	Desmosomal CadherinsIBA 01/2009

Therapy/Procedure

17	Therapeutics 05/2022 - 05/2003
3	Immunotherapy 01/2020 - 03/2017
2	Cell Transplantation 01/2019 - 07/2015
2	Hematopoietic Stem Cell Transplantation 03/2017 - 01/2016
1	Injections 01/2019
1	Heterologous Transplantation (Xenotransplantation) 06/2010